Topotarget is a Scandinavian-based late-stage clinical development oncology company. Topotarget aims at improving the quality of and prolonging the lives of cancer patients by offering novel, safe, and effective cancer drugs. Our lead compound, belinostat, is a Histone Deacetylase (HDAC) inhibitor that is being tested in a number of clinical trials.